NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection
London, UK, 22 May 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round.
The additional investment from Bristol Myers Squibb will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (‘MMR’) pathway in cancer, as well as further progress its pre-clinical studies and deliver a candidate drug in 2025.
